2 after Major Vascular Surgery

- 3 Molly Ratner MD<sup>1\*</sup>, Karan Garg MD<sup>1\*</sup>, Heepeel Chang MD<sup>2</sup>, Anjali Nigalaye MD<sup>3</sup>, Steven
- 4 Medvedosky BS<sup>1</sup>, Glenn Jacobowitz MD<sup>1</sup>, Jeffrey J Siracuse MD<sup>4</sup>, Virendra Patel MD<sup>5</sup>, Marc
- 5 Schermerhorn MD<sup>6</sup>, Charles DiMaggio PhD<sup>1</sup>, Caron B Rockman MD<sup>1</sup>
- 7 Division of Vascular and Endovascular Surgery, Department of Surgery, New York University
- 8 Langone Medical Center, New York, NY.
- <sup>2</sup>Division of Vascular Surgery, Department of Surgery, Westchester Medical Center, Valhalla,
- 10 NY.

19

21

22

23

- <sup>3</sup> Division of Hospitalist Medicine, Department of Medicine, Mount Sinai Beth Israel Hospital,
- 12 New York, NY.
- <sup>4</sup>Division of Vascular and Endovascular Surgery, Department of Surgery, Boston Medical
- 14 Center, Boston, Massachusetts
- <sup>5</sup>Division of Vascular and Endovascular Interventions, Department of Surgery, New York
- 16 Presbyterian- Columbia University Irving Medical Center, New York, NY
- <sup>6</sup>Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess
- 18 Medical Center, Boston, Massachusetts
- 20 \*Drs Molly Ratner and Karan Garg contributed equally to this manuscript.

**Pre-publication Corresponding Author** Molly Ratner, MD Division of Vascular and Endovascular Surgery Department of Surgery New York University Langone Medical Center, NYU Grossman School of Medicine 550 First Avenue, New York, NY 10016, USA Phone: 212-263-7311 Molly.ratner@nyulangone.org Word Count: 4952 

**Abstract Background:** The objective of this study was to examine the effect of COVID-19 vaccination on perioperative outcomes after major vascular surgery. **Methods:** This is a multicenter retrospective study of patients who underwent major vascular surgery between December 2021 through August 2023. The primary outcome was all-cause mortality within 30 days of index operation or prior to hospital discharge. Multivariable models were used to examine the association between vaccination status and the primary outcome. **Results:** Of the total 85,424 patients included, 19161 (22.4%) were unvaccinated. Unvaccinated patients were younger compared to vaccinated patients (mean age 68.44 +/- 10.37 years vs 72.11 +/- 9.20 years, p <.001) and less likely to have comorbid conditions, including hypertension (87.2% vs 89.7%, p < .001), congestive heart failure (14.5% vs 15.9%, p < .001), chronic obstructive pulmonary disease (35.7% vs 36.3, p < .001) and renal failure requiring hemodialysis (1.4% vs 1.7%, p = .005). After risk factor adjustment, vaccination was associated with decreased mortality (OR 0.7, 95% CI 0.62 - 0.81, p < .0001). Stratification by procedure type demonstrated that vaccinated patients had decreased odds of mortality after open AAA (OR 0.6, 95% CI 0.42-0.97, p = 0.03), EVAR (OR 0.6, 95% CI 0.43-0.83, p 0.002), CAS (OR 0.7, 95% CI 0.51-0.88, p = 0.004) and infra-inguinal lower extremity interventions (OR 0.7, 95% CI 0.48-0.96, p = 0.03).

## **Conclusions:**

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

COVID-19 vaccination is associated with reduced perioperative mortality in patients undergoing vascular surgery. This association is most pronounced for patients undergoing aortic aneurysm repair, carotid stenting and infrainguinal bypass.

Introduction

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Although primarily an infection of the respiratory tract, Coronavirus Disease 2019 (COVID-19) generates a systemic inflammatory state leading to dysregulation of and injury to multiple organ systems, <sup>1–5</sup> including the vasculature. <sup>6,7</sup> In the perioperative period, it has been proposed that the exaggerated immune response elicited by both surgical trauma and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be responsible for the increased risk of perioperative mortality and morbidity in patients with active or recent infections.<sup>8,9</sup> These findings have prompted groups like the American Society of Anesthesiologists to recommend delaying elective surgery in patients with COVID-19. 10 However, as the pandemic enters a new phase with widespread population immunity in the setting of vaccine development and/or prior infection, risk stratification will need to reflect these changes. COVID-19 vaccination has been associated with improved outcomes, including decreased mortality, in patients undergoing various surgical procedures, such as cardiovascular, gastrointestinal operations and orthopedic surgeries. <sup>11–13</sup> However, there is a paucity of literature evaluating the effect of COVID-19 vaccination on perioperative outcomes after major vascular surgery, specifically. In this retrospective cohort study, we utilized the Society for Vascular Surgery Vascular Quality Initiative (SVS-VQI) database to examine national trends in

perioperative mortality after major vascular surgery in the post-vaccination stage of the

## Methods

pandemic.

Data Source

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

7

failure requiring hemodialysis (HD) and preoperative medication utilization. The urgency of the case (i.e. elective vs urgent/emergent) was additionally considered a potential confounder. Outcomes: The primary outcome was perioperative all-cause mortality, defined as occurring either prior to discharge from the hospital or within 30 days of index operation. The secondary endpoints were surgery-specific perioperative mortality. Statistical Analysis All analyses were conducted in the R statistical software program. Comparisons of continuous variables were based on t-tests and categorical variables were compared using Chi Square tests as part of the CreatTableOne function of the R tableone package. Unadjusted odds ratios (ORs) for the association of COVID vaccination with perioperative mortality were calculated using the epitab function of the R epitools package. Separate multivariable logistic regression models for each type of procedure (open repair, EVAR, TEVAR, carotid endarterectomy, carotid artery stenting, infrainguinal and suprainguinal revascularization) comparing the association of COVID vaccination with perioperative mortality were adjusted for confounding by age, gender, hypertension, diabetes, race, ethnicity, pre-operative history of smoking and whether the procedure was elective or urgent. A single model with an additional control variable for the type of procedure was run for the full combined data. An additional multilevel model which set the intercept to vary by procedure type was created to establish a baseline risk for mortality risk for each procedure cohort. Results of the multivariable and multilevel models are presented as ORs with associated p-values and 95% confidence intervals (CIs).

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

8

After adjusting for age, gender, race, ethnicity, smoking status, hypertension, diabetes, coronary artery disease and dialysis, vaccinated status was associated with decreased mortality (OR 0.7, 95% CI 0.62 - 0.81, p <0.001). A multilevel model with the same variables in the multivariable logistic model with a random intercept by procedure type returned the same estimate for the

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

9

unvaccinated and vaccinated patients who underwent TEVAR.

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

Carotid Artery Revascularization (Table III) Similar to the overall patient cohort, vaccinated patients undergoing CAS and CEA were more likely to have a variety of medical comorbidities including hypertension, diabetes, and CHF. Notably, however, they were less likely than unvaccinated patients to have a history of CVD (54% vs 59.6%, p <0.001; 48.8% vs 55.2%, p <0.001). Vaccinated patients who underwent carotid revascularization were more likely to be on an aspirin, statin, ACE-inhibitor, or betablocker. Vaccinated patients who underwent CAS were less likely to have a positive covid diagnosis (1.0% vs 1.6%, p < .001) and peri-operative mortality was significantly reduced compared to the unvaccinated cohort (0.7% vs 1.3%, p <0.001). There was no significant difference in covid status or perioperative mortality between unvaccinated and vaccinated patients who underwent CEA. Peripheral Revascularization (Table IV) Unlike the overall study population or patients undergoing infra-inguinal bypass, white patients were over-represented in the unvaccinated cohort who underwent supra-inguinal bypass (82.9% vs 75.2%, p <0.001). Vaccinated patients who underwent peripheral revascularization were more likely to have a history of HTN, diabetes, and HD and to be on ACE-inhibitors or beta-blockers. In patients undergoing supra-inguinal bypass, there was no significant difference in the likelihood of undergoing an elective procedure between vaccinated and unvaccinated patients. In patients with underwent either supra- or infrainguinal bypass, there was no significant difference in the proportion of vaccinated and unvaccinated patients with a positive COVID diagnosis and there was no significant difference in perioperative mortality.

**Discussion** 

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

In this retrospective analysis of a large, multicenter database, vaccination against COVID was significantly associated with reduced perioperative mortality after major vascular surgery. Despite presenting with a high burden of comorbid conditions, including hypertension, diabetes and coronary artery disease, vaccinated patients had reduced odds of perioperative mortality after open AAA, EVAR, CAS, and infra-inguinal lower extremity open revascularization procedures. Our results underscore the efficacy of the COVID vaccination in reducing perioperative all-cause mortality, particularly in older, high-risk patients. Recently published reports have examined the protective effect of COVID vaccination amongst a different subset of surgical patients. In a retrospective, multicenter cohort review of patients undergoing high risk surgery, Sharath et al found that the unadjusted and adjusted 90-day mortality rates between vaccinated patients with and without a recent COVID-19 diagnosis were comparable. Moreover, in a subgroup analysis of matched vaccinated and unvaccinated COVID positive patients, vaccination reduced 90-day mortality by close to 50%. 15 In a second. retrospective study of cardiac surgery patients, a cohort with similar risk factors to those undergoing vascular surgery, Blumenfeld et al examined the effect of perioperative COVID-19 infection on 30-day mortality before and after the development of the COVID vaccine. The authors reported a significantly elevated risk of perioperative mortality in COVID-19 positive patients prior to vaccine availability. However, after universal vaccination protocols were put in place, the association between COVID-19 infection and increased perioperative mortality was no longer apparent. 16 Although further research is needed, it has been proposed that the reduced

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

mortality may be attributed to effectiveness of the vaccine in quelling the systemic inflammatory state induced by virus which is further heightened in the context of surgery. 15 The reduced all-cause mortality seen in our study population of largely COVID negative patients cannot be fully explained by the effectiveness of the vaccine in preventing COVID-19-related deaths. A similar reduction in all-cause mortality was observed in a population-based study out of Australia, in which the authors proposed several possible explanations for this finding, including indirect reduction in outcomes associated with COVID-19 infection, such as cardiovascular and pulmonary complications. <sup>17</sup> Given that vascular surgery patients are amongst the highest risk patients for postoperative cardiac complications, <sup>18</sup> this hypothesis seems reasonable. An additional consideration brought forth by the authors was the effect of confounding, particularly in the form of behavioral differences such as the healthy vaccinee effect.<sup>17</sup> However, it is worth nothing that vaccinated patients within our study tended to present with more serious comorbid conditions which we believe reduces the likelihood that vaccination status is a simply a marker for access to and trust in the health care system. The higher proportion of older and sicker patients who were vaccinated in our study is consistent with epidemiologic data within the United States. In the 2021, United States Census Bureau's Household Pulse Survey of around 61,000 people, unvaccinated people were generally younger with 75% of the unvaccinated population under the age of 50. 19 This pattern of vaccination can be at least partially attributed to the way the COVID vaccine was rolled out in most states with priority given to older adults and those living in group living facilities. However, beyond

logistics, it is conceivable to believe that patients who are aware of serious comorbid conditions

may be more likely to vaccinate for specifically that reason, given the widespread knowledge that people with these risk factors generally had worse outcomes with COVID infections. In fact, studies have described the relationship between increasing age or pre-existing medical conditions and the intention to vaccinate. <sup>20–22</sup>The US Census Survey additionally reported a higher representation of non-Hispanic Black people within the unvaccinated cohort compared to the vaccinated cohort (13% vs 11%), <sup>19</sup> a finding mirrored within our own study population. The significance of this disparity cannot be understated, particularly given the disproportionate impact of both COVID 19 and atherosclerotic cardiovascular disease on black individuals. <sup>23</sup> A more comprehensive understanding of what drives vaccine hesitancy amongst vascular surgery patients should be undertaken to better address this issue.

During the height of the pandemic, major society guidelines suggested deferring elective procedures for several weeks after COVID-19 infection.<sup>10</sup> However, in the endemic phase of COVID-19, as more patients have been exposed to the virus through infection and immunization, guidelines around surgical timing are in flux. The results of our study, in conjunction with others, <sup>15,24</sup> suggests a protective effect of vaccination prior to surgery, particularly in patients whose risk factors predispose them to needing surgical intervention in urgent or emergent settings, such as those with vascular disease. However, further studies are needed to discern optimal timing between vaccination and operative intervention to provide greatest protection.

There are several limitations to this study, including its retrospective observational nature. While the use of the VQI-SVS database allowed us to capture a broader population, however, the registry lacks granular detail. For instance, the extent of vascular disease with regards to anatomy

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

## REFERENCES

- 1. Inciardi RM, Solomon SD, Ridker PM, Metra M. Coronavirus 2019 Disease (COVID-19),
- 323 Systemic Inflammation, and Cardiovascular Disease. *JAHA*. 2020;9(16):e017756.
- 324 doi:10.1161/JAHA.120.017756
- 2. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19.
- 326 Am J Emerg Med. 2020;38(7):1504-1507. doi:10.1016/j.ajem.2020.04.048
- 32. Janardhan V, Janardhan V, Kalousek V. COVID-19 as a Blood Clotting Disorder
- Masquerading as a Respiratory Illness: A Cerebrovascular Perspective and Therapeutic
- 329 Implications for Stroke Thrombectomy. *J Neuroimaging*. 2020;30(5):555-561.
- 330 doi:10.1111/jon.12770
- 4. Chen YT, Shao SC, Hsu CK, Wu IW, Hung MJ, Chen YC. Incidence of acute kidney injury
- in COVID-19 infection: a systematic review and meta-analysis. Crit Care. 2020;24(1):346.
- 333 doi:10.1186/s13054-020-03009-y
- 5. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver
- involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet*
- 336 Gastroenterol Hepatol. 2020;5(7):667-678. doi:10.1016/S2468-1253(20)30126-6
- 6. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients
- with COVID-19. *Lancet Haematol*. 2020;7(6):e438-e440. doi:10.1016/S2352-
- 339 3026(20)30145-9

- 340 7. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in 341 hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995-2002. 342 doi:10.1111/jth.14888 343 8. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing 344 surgery with perioperative SARS-CoV-2 infection: an international cohort study. *Lancet*. 345 2020;396(10243):27-38. doi:10.1016/S0140-6736(20)31182-X 346 9. Doglietto F, Vezzoli M, Gheza F, et al. Factors Associated With Surgical Mortality and 347 Complications Among Patients With and Without Coronavirus Disease 2019 (COVID-19) in 348 Italy. JAMA Surg. 2020;155(8):691-702. doi:10.1001/jamasurg.2020.2713 349 10. Anesthesia Patient Safety Foundation. American Society of Anesthesiologists and 350 Anesthesia Patient Safety Foundation joint statement on elective surgery and anesthesia for 351 patients after COVID-19 infection. Accessed January 20, 2024. https://www.apsf.org/news-352 updates/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-for-patients-aftercovid-19-infection/ 353 11. Jagadeesh N, Gnany J, Kapadi S, Koshy N, Shaw D. COVID-19 Vaccination: Does It Alter 354 355 Postoperative Mortality and Morbidity in Hip Fractures? Cureus. 2022;14(12):e32688. 356 doi:10.7759/cureus.32688 357 12. Prasad NK, Lake R, Englum BR, et al. COVID-19 Vaccination Associated With Reduced
- 358 Postoperative SARS-CoV-2 Infection and Morbidity. *Annals of Surgery*. 2022;275(1):31-36.
  359 doi:10.1097/SLA.000000000005176

13. Prasad NK, Englum BR, Mayorga-Carlin M, et al. Partial COVID-19 vaccination associated 360 361 with reduction in postoperative mortality and SARS-CoV-2 infection. Am J Surg. 362 2022;224(4):1097-1102. doi:10.1016/j.amjsurg.2022.03.038 363 14. Mesbah Oskui P, Kloner RA, Burstein S, et al. The safety and efficacy of peripheral vascular 364 procedures performed in the outpatient setting. J Invasive Cardiol. 2015;27(5):243-249. 365 15. Sharath SE, Kougias P, Daviú-Molinari T, Faridmoayer E, Berger DH. Association Between 366 Coronavirus Disease 2019 Vaccination and Mortality After Major Operations. Annals of 367 Surgery. 2024;279(1):58-64. doi:10.1097/SLA.0000000000000051 368 16. Blumenfeld O, Rosenberg A, Reuven M, Caspi I, Sharoni E, Leviner DB. The effect of 369 COVID-19 vaccination on 30-day mortality after cardiac surgery – Insights from the Israel 370 national registries. Infection Prevention in Practice. 2024;6(1):100334. 371 doi:10.1016/j.infpip.2023.100334 372 17. Liu B, Stepien S, Dobbins T, et al. Effectiveness of COVID-19 vaccination against COVID-373 19 specific and all-cause mortality in older Australians: a population based study. The Lancet 374 Regional Health - Western Pacific. 2023;40:100928. doi:10.1016/j.lanwpc.2023.100928 375 18. Beaulieu RJ, Sutzko DC, Albright J, Jeruzal E, Osborne NH, Henke PK. Association of High 376 Mortality With Postoperative Myocardial Infarction After Major Vascular Surgery Despite

Use of Evidence-Based Therapies. JAMA Surg. 2020;155(2):131.

378 doi:10.1001/jamasurg.2019.4908

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

19. US Bureau of Census. Household Pulse Survey Data. Published online 2021. Accessed January 1, 2024. https://www.census.gov/programs-surveys/household-pulsesurvey/data.html 20. Daly M, Robinson E. Willingness to Vaccinate Against COVID-19 in the U.S.: Representative Longitudinal Evidence From April to October 2020. American Journal of Preventive Medicine. 2021;60(6):766-773. doi:10.1016/j.amepre.2021.01.008 21. Ruiz JB, Bell RA. Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey. Vaccine. 2021;39(7):1080-1086. doi:10.1016/j.vaccine.2021.01.010 22. Trent M, Seale H, Chughtai AA, Salmon D, MacIntyre CR. Trust in government, intention to vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the United States, United Kingdom, and Australia. Vaccine. 2022;40(17):2498-2505. doi:10.1016/j.vaccine.2021.06.048 23. Carnethon MR, Pu J, Howard G, et al. Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association. Circulation. 2017;136(21). doi:10.1161/CIR.0000000000000534 24. Le ST, Kipnis P, Cohn B, Liu VX. COVID-19 Vaccination and the Timing of Surgery Following COVID-19 Infection. *Annals of Surgery*. 2022;276(5):e265-e272. doi:10.1097/SLA.0000000000005597

Table I: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing major vascular surgery

Diabetes	6957 (36.3%)	24225 (36.5%)	0.53
Hypertension	16700 (87.2%)	59442 (89.7%)	<0.001
Former Smoker	7260 (37.9%)	33248 (50.2%)	<.001
Current Smoker	7245 (37.8%)	16896 (25.5%)	<0.001
Black	1584 (8.3%)	5009 (7.6%)	.001
White	16191 (84.5%)	56359 (85.1%)	0.06
Race			
Male	12461 (65.0%)	43479 (65.6%)	0.14
Age (mean +/- SD)	68.44 +/- 10.37	72.11 +/- 9.20	<0.001
	Unvaccinated (n = 19161)	Vaccinated (n = 66263)	P Value

2771 (14.5%)	10523 (15.9%)	<0.001
5423 (35.7%)	17633 (36.3%)	<0.001
270 (1.4%)	1129 (1.7%)	0.005
3		
14413 (75.2%)	51610 (77.9%)	<0.001
14925 (77.9%)	56021 (84.7%)	<0.001
9546 (49.8%)	35075 (53.0%)	<0.001
9470 (49.4%)	32123 (48.5%)	0.02
2511 (13.1%)	9698 (14.6%)	<0.001
8606 (44.9%)	33354 (50.4%)	<0.001
14593 (76.2%)	55252 (83.5%)	<0.001
358 (1.9%)	734 (1.1%)	<0.001
360 (1.8%)	761 (1.1%)	<0.001
	5423 (35.7%)  270 (1.4%)  14413 (75.2%)  14925 (77.9%)  9546 (49.8%)  9470 (49.4%)  2511 (13.1%)  8606 (44.9%)  14593 (76.2%)  358 (1.9%)	5423 (35.7%)       17633 (36.3%)         270 (1.4%)       1129 (1.7%)         14413 (75.2%)       51610 (77.9%)         14925 (77.9%)       56021 (84.7%)         9546 (49.8%)       35075 (53.0%)         9470 (49.4%)       32123 (48.5%)         2511 (13.1%)       9698 (14.6%)         8606 (44.9%)       33354 (50.4%)         14593 (76.2%)       55252 (83.5%)         358 (1.9%)       734 (1.1%)

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ACE-inhibitor, angiotensin converting enzyme inhibitor Bold faced p values indicate significance.

Table II: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing aortic surgery

		OPEN			EVAR TEVA			TEVAR	VAR	
Variable	Unvaccinated (n= 394)	Vaccinated (n = 1559)	P value	Unvaccinated (n= 2149)	Vaccinated (n= 8970)	P value	Unvaccinated (n = 1075)	Vaccinated (n = 3404)	P value	
Age (mean +/-SD)	67.29 +/- 9.22	69.90 +/- 8.38	<0.001	71.76 +/- 9.08	74.28 +/- 8.38	<0.001	65.64 +/- 13.30	70.91 +/- 11.11	<0.001	
Male	283 (71.8%)	1179 (75.6%)	0.14	1709 (79.5%)	7214 (80.5)	0.60	711 (66.1%)	2250 (66.1)	0.73	
Race										
White	331 (84.0%)	1204 (77.3%)	0.004	151 (7.0%)	563 (6.3%)	.20	674 (62.7%)	2360 (69.4%)	<0.001	
Black	22 (5.6%)	78 (5.0%%)	0.64	1801 (83.9%)	7539 (84.1%)	.85	242 (22.5%)	535 (15.7%)	<0.001	
Current Smoker	147 (37.4%)	757 (48.7%)	<0.001	939 (43.8%)	2673 (29.8%)	<0.001	432 (40.3%)	978 (28.8%)	<0.001	
Former Smoker	204 (51.9%)	630 (40.5%)	<0.001	909 (42.4%)	4985 (55.6%)	<0.001	380 (35.4%)	1664 (48.9%)	<0.001	

Hypertension	318 (80.7%)	1305 (83.8%)	0.16	1794 (83.5%)	7698 (85.9%)	0.005	979 (91.2%)	3099 (91.1%)	0.98
Diabetes	64 (16.2%)	271 (17.4%)	0.64	442 (20.6%)	1924 (21.5%)	0.38	164 (15.3%)	665 (19.5%)	0.002
CAD	82 (20.8%)	348 (22.4%)	0.54	574 (26.7%)	2509 (28.0%)	0.24	195 (18.1%)	727 (21.4%)	0.02
Prior CABG	43 (10.9%)	174 (11.2%)	0.95	297 (13.8%)	1328 (14.8%)	0.26	93 (8.7%)	400 (11.8%)	0.006
Prior PCI	67 (17.0%)	290 (18.6%)	0.50	478 (22.3%)	2048 (22.9%)	0.59	147 (13.7%)	576 (16.9%)	0.01
CHF	33 (8.4%)	156 (10.0%)	0.37	304 (14.2%)	1319 (14.7%)	0.53	190 (17.7%)	574 (16.9%)	0.57
COPD	128 (32.5%)	524 (33.7%)	0.71	747 (34.8%)	3096 (34.5%)	0.86	352 (32.7%)	1157 (34.0%)	0.47
Hemodialysis	2 (0.5%)	8 (0.5%)	1.00	27 (1.3%)	96 (1.1%)	0.53	30 (2.8%)	91 (2.7%)	0.92
Preop									
Medications									
Aspirin	207 (52.7%)	923 (59.4%)	0.02	1207 (56.2%)	5255 (58.7%)	0.04	575 (53.5%)	2015 (59.3%)	0.001
Statins	242 (61.6%)	1193 (76.7%)	<0.001	1415 (65.9%)	6822 (76.2%)	<0.001	618 (57.5%)	2416	<0.001

								(71.1%)	
ACE-	152 (38.7%)	738 (47.4%)	0.002	975 (45.4%)	4310 (48.1%)	0.02	488 (45.4%)	1561 (45.9%)	0.82
P2Y <sub>12</sub> nhibitors	32 (8.1%)	126 (8.1%)	1.00	333 (15.5%)	1195 (13.3%)	0.01	144 (13.4%)	406 (11.9%)	0.22
Anticoagulati on	37 (9.4%)	206 (13.2%)	0.05	337 (15.7%)	1572 (17.5%)	0.04	163 (15.2%)	630 (18.5%)	0.01
Beta- blocker	168 (42.9%)	760 (48.8%)	0.04	1004 (46.8%)	4555 (50.8%)	0.001	730 (67.9%)	2248 (66.0%)	0.27
Elective	281 (71.3%)	1210 (77.6%)	0.01	1631 (76.2%)	7787 (86.9%)	<0.001	706 (65.7%)	2694 (79.2%)	<0.001
Positive COVID Status	16 (4.1%)	14 (0.9%)	<0.001	41 (1.9%)	103 (1.2%)	0.005	26 (2.4%)	58 (1.7%)	0.13
Mortality	42 (10.7%)	111 (7.1%)	0.02	67 (3.1%)	127 (1.4%)	<0.001	57 (5.3%)	141 (4.2%)	0.11

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.

Table III: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing carotid artery revascularization

		CAS		CEA				
Variable	Unvaccinated	Vaccinated.	Davalara	Unvaccinated	Vaccinated	D. Walna		
	(n = 6933)	(n = 22308)	P value	(n = 5790)	(n = 20506)	P Value		
A 22 (magn + / SD)	69.83 +/-	72 16 . / 9 09	-0.001	(0.07 . / 0.52	72.02 . / 9.61	-0.001		
Age (mean +/- SD)	10.18	73.16 +/- 8.98	<0.001	69.07 + /- 9.53	/2.02 +/- 8.01	<0.001		
Male	4306 (62.1%)	14008 (62.8%)	0.30	3509 (60.6%)	12288 (59.9%)	0.58		
Race								
White	6075 (87.7%)	19881 (89.1%)	0.001	5157 (89.1%)	18331 (89.5%)	0.42		
Black	442 (6.4%)	1270 (5.7%)	0.04	280 (4.8%)	1065 (5.2%)	0.27		
Current Smoker	2245 (32.5%)	4481 (20.1%)	<0.001	1915 (33.1%)	4515 (22.0%)	<0.001		
Former Smoker	2660 (38.5%)	11152 (50.0%)	<0.001	2265 (39.1%)	10194 (49.7%)	<0.001		
Hypertension	6089 (87.9%)	20235 (90.7%)	<0.001	5161 (89.1%)	18604 (90.8%)	<0.001		
Diabetes	2585 (37.3%)	8826 (39.6%)	0.001	2110 (36.4%)	7911 (38.6%)	<0.001		
CAD	3141 (45.3%)	10805 (48.5%)	<0.001	1618 (27.9%)	5527 (27.0%)	0.15		

Prior CABG	1126 (16.3%)	4233 (19.0%)	<0.001	958 (16.6%)	3604 (17.6%)	0.07
Prior PCI	1659 (24.0%)	5826 (26.2%)	<0.001	1239 (21.4%)	4506 (22.0%)	0.35
CHF	1038 (15.0%)	3759 (16.9%)	<0.001	710 (12.3%)	2781 (13.6%)	0.01
COPD	1636 (23.6%)	5282 (23.7%)	0.89	1343 (23.2%)	4696 (22.9%)	0.66
CVD	4127 (59.6%)	12031 (54.0%)	<0.001	3196 (55.2%)	9997 (48.8%)	<0.001
Hemodialysis	89 (1.3%)	286 (1.3%)	1.00	48 (0.8%)	217 (1.1%)	0.14
Preoperative						
Medications						
Aspirin	5745 (82.9%)	19499 (87.5%)	<0.001	4707 (81.4%)	17086(83.4%)	<0.001
Statin	5721 (82.6%)	19679 (88.3%)	<0.001	4757 (82.2%)	18066(88.2%)	<0.001
ACE-inhibitor	3483 (50.3%)	12064 (54.1%)	<0.001	3057 (52.8%)	11287 (55.1%)	0.002
P2Y <sub>12</sub> -inhibitor	5522 (79.7%)	19057 (85.5%)	<0.001	2459 (42.5%)	8320 (40.6%)	0.01
Anticoagulation	409 (6.4%)	1463 (7.3%)	0.02	784 (13.5%)	3091 (15.1%)	0.004
Beta-blocker	3085 (44.5%)	11207 (50.3%)	<0.001	2448 (42.3%)	9815 (47.9%)	<0.001
Elective	5201 (75.1%)	18367 (82.5%)	<0.001	4696 (81.1%)	17845 (87.0%)	<0.001
Positive COVID	114 (1.6%)	216 (1.0%)	<.001	110 (1.2%)	208 (1.0%)	.20

Status						
Mortality	88 (1.3%)	157 (0.7%)	<.001	22 (0.4%)	62 (0.3%)	.36

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; CVD, cerebrovascular disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.

Table IV: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing revascularization for peripheral artery disease.

		SUPRAINGUINAL			INFRAINGUINAL	,
	Unvaccinated	Vaccinated	P Value	Unvaccinated	Vaccinated	P Value
	(N = 620)	(N = 1635)	1 Value	(n = 2200)	(n = 7881)	1 value
Age (mean +/- SD)	62.15 +/- 9.866	66.81 +/- 9.682	<0.001	64.90 +/-10.412	68.87 +/- 9.928	<0.001
Male	383 (61.8%)	957 (58.5%)	0.32	1560 (70.9%)	5584 (70.9%)	0.87
Race						0.10
White	513 (82.9%)	1228 (75.2%)	<0.001	1640 (74.5%)	5816 (73.8%)	0.51
Black	65 (10.5%)	190 (11.6%)	0.45	382 (17.4%)	1308 (16.6%)	0.40
Current Smoker	407 (65.6%)	816 (49.9%)	<0.001	1160 (52.8%)	2804 (35.6%)	<0.001
Former Smoker	192 (31.0%)	745 (45.6%)	<0.001	710 (32.3%)	3751 (47.6%)	<0.001
Hypertension	502 (81.1%)	1393 (85.3%)	0.02	1857 (84.5%)	7108 (90.2%)	<0.001
Diabetes	164 (26.5%)	526 (32.2%)	0.01	1068 (48.6%)	4102 (52.1%)	0.01
CAD	158 (25.5%)	402 (24.7%)	0.68	654 (31.3%)	2283 (30.5%)	0.49
Prior CABG	56 (9.0%)	209 (12.8%)	0.01	371 (16.9%)	1490 (18.9%)	0.03

Prior PCI	109 (17.6%)	285 (17.4%)	0.94	518 (23.6%)	1850 (23.5%)	0.94
CHF	67 (10.8%)	219 (13.4%)	0.10	429 (19.5%)	1715 (21.8%)	0.02
COPD	208 (33.5%)	644 (39.4%)	0.01	619 (28.2%)	2234 (28.4%)	0.87
Hemodialysis	5 (0.8%)	38 (2.3%)	0.02	69 (3.1%)	393 (5.0%)	<0.001
Preoperative						
Medications						
Aspirin	445 (71.9%)	1177 (72.0%)	0.96	1527 (69.4%)	5655 (71.8%)	0.03
Statin	485 (78.4%)	1319 (80.7%)	0.22	1687 (76.8%)	6526 (82.9%)	<0.001
ACE-inhibitor	279 (45.1%)	831 (50.8%)	0.02	1112 (50.6%)	4284 (54.4%)	0.002
P2Y <sub>12</sub> -inhibitor	154 (24.9%)	354 (21.7%)	0.10	826 (37.6%)	2665 (33.8%)	0.001
AC	140 (22.6%)	343 (22.0%)	0.40	641 (29.1%)	2393 (30.4%)	0.27
Beta-blocker	222 (35.9%)	687 (42.0%)	0.01	949 (43.2%)	4082 (51.8%)	<0.001
Elective	461 (74.5%)	1259 (77.1%)	0.20	1617 (73.6%)	6090 (77.3%)	<0.001
Positive COVID						
Status	10 (1.6%)	21 (1.3%)	0.55	41 (1.9%)	114 (1.4%)	0.16
Mortality	25 (4.0%)	59 (3.6%)	0.64	34 (1.5%)	104 (1.3%)	0.42

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; CVD, cerebrovascular disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.

Figure 1: Forest Plot Evaluating COVID Vaccination Status and Mortality

